Opendata, web and dolomites

GutILC3

Cell-cell interactions critical to ILC3 function in the human gut

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GutILC3 project word cloud

Explore the words cloud of the GutILC3 project. It provides you a very rough idea of what is the project "GutILC3" about.

conferring    feasibility    me    cells    papers    inappropriate    techniques    ultimate    patient    host    building    mouse    producing    provides    mononuclear    group    seem    optimal    inflammatory    gamma    cd4    22    ensures    immune    monitoring    bowel    hosting    inflammation    career    colitis    human    purpose    lymphoid    progression    cancer    microbes    cellular    unknown    truly    intestinal    therapy    modulating    ibd    phagocytes    training    reporting    direct    translational    insights    manner    skill    exact    possibilities    maintaining    crosstalk    society    molecules    risk    il    excellent    crc    pinpoint    track    mucosal    therapies    dramatically    extensive    prospects    unravel    ilcs    etiology    interactions    interacting    infrastructure    materials    intestine    susceptible    model    record    degree    players    colorectal    interestingly    genetically    innate    homeostasis    discovered    interaction    ilc3    suitable    critical    utilizes    ifn    disease    17   

Project "GutILC3" data sheet

The following table provides information about the project.

Coordinator
KAROLINSKA INSTITUTET 

Organization address
address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177
website: www.ki.se

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 173˙857 €
 EC max contribution 173˙857 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2015
 Duration (year-month-day) from 2015-04-01   to  2017-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET SE (STOCKHOLM) coordinator 173˙857.00

Map

 Project objective

Inflammatory bowel disease (IBD), conferring a dramatically increased risk for development of colorectal cancer (CRC), results from an inappropriate inflammatory response to intestinal microbes in a genetically susceptible host. However, the exact etiology of IBD is unknown. Building up on high impact papers from the host group reporting on the recently discovered innate lymphoid cells (ILCs) as key players in mucosal inflammation, I now aim to unravel the role for ILCs in IBD and CRC. Interestingly, while the IL-22 producing ILC3 seem to be crucial in maintaining intestinal homeostasis, the IL-17 and IFN-gamma-producing ILCs can cause inflammation in a mouse model of colitis and are present in human IBD. Furthermore, ILCs were recently described to be involved in modulating immune responses, by interacting with CD4 T cells and mononuclear phagocytes in the mouse intestine. I aim to identify critical pathways in the crosstalk of ILC3 with other immune cells in the human intestine. The ultimate purpose is to assess how these interactions affect immune homeostasis and disease progression in IBD and CRC. We will pinpoint crucial interaction molecules and cellular processes that can be used for monitoring current therapies as well as finding new therapy targets for IBD and CRC. This truly translational proposal utilizes, in an optimal manner, unique state-of-the-art techniques and patient materials to provide novel insights into the etiology of IBD and CRC. The excellent track record of the hosting group, the highly suitable infrastructure provided by the host institution and my own extensive research experience ensures a high degree of feasibility. Furthermore, this project provides excellent training opportunities, skill advancement possibilities and career prospects for me and its results are expected to have a direct impact on the European society.

 Publications

year authors and title journal last update
List of publications.
2015 V. Konya, J. Mjösberg
Innate Lymphoid Cells in Graft-Versus-Host Disease
published pages: 2795-2801, ISSN: 1600-6135, DOI: 10.1111/ajt.13394
American Journal of Transplantation 15/11 2019-07-23
2016 Åsa K Björklund, Marianne Forkel, Simone Picelli, Viktoria Konya, Jakob Theorell, Danielle Friberg, Rickard Sandberg, Jenny Mjösberg
The heterogeneity of human CD127+ innate lymphoid cells revealed by single-cell RNA sequencing
published pages: 451-460, ISSN: 1529-2908, DOI: 10.1038/ni.3368
Nature Immunology 17/4 2019-07-23
2016 Viktoria Konya, Jenny Mjösberg
Lipid mediators as regulators of human ILC2 function in allergic diseases
published pages: 36-42, ISSN: 0165-2478, DOI: 10.1016/j.imlet.2016.07.006
Immunology Letters 179 2019-07-23

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GUTILC3" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GUTILC3" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

CYBERSECURITY (2018)

Cyber Security Behaviours

Read More  

LiverMacRegenCircuit (2020)

Elucidating the role of macrophages in liver regeneration and tissue unit formation

Read More  

ROSETTA (2020)

Deciphering the Role of aberrant glycOSylation in the rEsponse to Targeted TherApies for breast cancer

Read More